GSK Lymerix Withdrawn: Production Stopped, Inventory To Be Discarded
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
You may also be interested in...
Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.
Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.
FDA will update vaccines advisory committee on GlaxoSmithKline's Lymerix during the afternoon of May 21. The company withdrew the lyme disease vaccine Feb. 25, citing low demand. The committee had previously reviewed reports of safety problems with the vaccine (11"The Pink Sheet" March 4, p. 23). The meeting will be held at the Hilton in Silver Spring, Md., at 8:30 a.m...